The necessity of early anti-inflammatory therapy in mild-to-moderate
COVID-19: A personal experience from an attending pharmacist and his
resident
- Parisa Ghasemiyeh,
- Soliman Mohammadi-Samani
Soliman Mohammadi-Samani
Shiraz University of Medical Sciences School of Pharmacy
Corresponding Author:smsamani@sums.ac.ir
Author ProfileAbstract
I am a professor and attending pharmacist in the field of pharmaceutical
sciences and writer or co-author of at least 5 manuscripts about
different aspects of COVID-19. More than 15 months from the first report
of COVID-19, over 120 million people all over the world infected by this
virus, and more than 2.5 million of them have died. Although different
treatment approaches have been proposed, management of the COVID-19
patients is steal remained controversial. In this regard, I want to
share my personal experience from the exposure to the coronavirus and
the consequence of this infection on my health status. I am a 51 years
old male, known case of hypertension, dyslipidemia, and chronic kidney
disease. During working hours of colleagues in the Faculty of Pharmacy,
I visited one of my colleagues in his office. After leaving the Faculty,
my colleague declares that his RT-PCR test of COVID-19 is positive and
it took 3 days for me to experience the first sign of the COVID-19 as
fever. Many complications have occurred for me during the different
stages of COVID-19 infection that I shared and explained in detail with
the suggested pharmacotherapies. According to the pathophysiology of
COVID-19 infection and my personal experience during COVID-19 infection,
I want to emphasize the necessity of early initiation of
anti-inflammatory agents including corticosteroids and colchicine in
high-risk patients with mild-to-moderate COVID-19 pneumonia who shows
respiratory system involvement, in order to prevent progression to the
severe and critical stages of this disease.